Doheny Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-4,714
| Closed | -$382K | – | 71 |
|
|
2023
Q4 | $382K | Sell |
4,714
-150
| -3% | -$11.7K | 0.37% | 52 |
|
|
2023
Q3 | $365K | Hold |
4,864
| – | – | 0.35% | 56 |
|
|
2023
Q2 | $375K | Hold |
4,864
| – | – | 0.32% | 57 |
|
|
2023
Q1 | $404K | Buy |
4,864
+2,500
| +106% | +$207K | 0.36% | 55 |
|
|
2022
Q4 | $203K | Sell |
2,364
-2,500
| -51% | -$198K | 0.24% | 66 |
|
|
2022
Q3 | $300K | Buy |
+4,864
| New | +$307K | 0.3% | 59 |
|
|
2022
Q1 | $305K | Sell |
5,124
-13,295
| -72% | -$850K | 0.22% | 65 |
|
|
2021
Q4 | $1.34M | Sell |
18,419
-3,920
| -18% | -$270K | 0.94% | 33 |
|
|
2021
Q3 | $1.56M | Hold |
22,339
| – | – | 1.12% | 30 |
|
|
2021
Q2 | $1.54M | Buy |
22,339
+12,515
| +127% | +$836K | 0.99% | 33 |
|
|
2021
Q1 | $635K | Buy |
9,824
+2,600
| +36% | +$168K | 0.43% | 58 |
|
|
2020
Q4 | $421K | Sell |
7,224
-31,055
| -81% | -$1.87M | 0.29% | 69 |
|
|
2020
Q3 | $2.42M | Sell |
38,279
-900
| -2% | -$62.4K | 2% | 15 |
|
|
2020
Q2 | $3.01M | Buy |
39,179
+10,550
| +37% | +$809K | 2.85% | 6 |
|
|
2020
Q1 | $1.86M | Hold |
28,629
| – | – | 1.47% | 25 |
|
|
2019
Q4 | $1.86M | Sell |
28,629
-8,010
| -22% | -$522K | 1.47% | 25 |
|
|
2019
Q3 | $2.32M | Sell |
36,639
-9,310
| -20% | -$609K | 2.02% | 14 |
|
|
2019
Q2 | $3.1M | Buy |
45,949
+5
| +0% | +$329 | 2.6% | 7 |
|
|
2019
Q1 | $2.99M | Buy |
45,944
+21,840
| +91% | +$1.45M | 2.54% | 8 |
|
|
2018
Q4 | $1.51M | Sell |
24,104
-3,475
| -13% | -$243K | 1.1% | 29 |
|
|
2018
Q3 | $2.13M | Buy |
27,579
+6,908
| +33% | +$522K | 1.11% | 31 |
|
|
2018
Q2 | $1.46M | Sell |
20,671
-14,335
| -41% | -$1.01M | 0.79% | 36 |
|
|
2018
Q1 | $2.64M | Buy |
35,006
+11,255
| +47% | +$895K | 1.39% | 22 |
|
|
2017
Q4 | $1.7M | Sell |
23,751
-3,295
| -12% | -$250K | 0.79% | 40 |
|
|
2017
Q3 | $2.19M | Buy |
27,046
+820
| +3% | +$62.7K | 1.01% | 27 |
|
|
2017
Q2 | $1.86M | Sell |
26,226
-5,465
| -17% | -$364K | 0.87% | 33 |
|
|
2017
Q1 | $2.15M | Sell |
31,691
-25,070
| -44% | -$1.76M | 0.97% | 25 |
|
|
2016
Q4 | $4.07M | Sell |
56,761
-5,370
| -9% | -$399K | 1.97% | 14 |
|
|
2016
Q3 | $4.92M | Sell |
62,131
-6,615
| -10% | -$537K | 2.53% | 13 |
|
|
2016
Q2 | $5.74M | Sell |
68,746
-775
| -1% | -$68.8K | 2.88% | 11 |
|
|
2016
Q1 | $6.39M | Sell |
69,521
-7,965
| -10% | -$718K | 3.29% | 7 |
|
|
2015
Q4 | $7.84M | Buy |
77,486
+180
| +0.2% | +$18.7K | 3.83% | 3 |
|
|
2015
Q3 | $7.59M | Sell |
77,306
-205
| -0.3% | -$22.8K | 3.93% | 3 |
|
|
2015
Q2 | $9.07M | Buy |
77,511
+450
| +0.6% | +$49.2K | 4.06% | 3 |
|
|
2015
Q1 | $7.56M | Sell |
77,061
-1,460
| -2% | -$148K | 3.51% | 3 |
|
|
2014
Q4 | $7.4M | Buy |
78,521
+275
| +0.4% | +$28.4K | 3.54% | 3 |
|
|
2014
Q3 | $8.33M | Sell |
78,246
-2,225
| -3% | -$218K | 4.17% | 3 |
|
|
2014
Q2 | $6.67M | Sell |
80,471
-863
| -1% | -$67.2K | 3.16% | 6 |
|
|
2014
Q1 | $5.76M | Buy |
81,334
+10,765
| +15% | +$844K | 2.96% | 7 |
|
|
2013
Q4 | $5.3M | Buy |
70,569
+27,173
| +63% | +$1.89M | 2.79% | 8 |
|
|
2013
Q3 | $2.73M | Buy |
43,396
+18,730
| +76% | +$1.12M | 1.5% | 28 |
|
|
2013
Q2 | $1.26M | Buy |
+24,666
| New | +$1.29M | 0.72% | 54 |
|
Other funds holding GILD
Doheny Asset Management's GILD Position: Q1 2024 in Review
Doheny Asset Management sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 4,714 shares — an estimated $382K sold.
Doheny Asset Management first reported a position in GILD in Q2 2013 and held it in 42 quarters. The position peaked at $9.07M in Q2 2015. 1,722 funds tracked by Wall St. Rank hold GILD as of Q1 2024.
- Doheny Asset Management reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
- Doheny Asset Management sold 4,714 Gilead Sciences shares in Q1 2024, an estimated $382K.
- Doheny Asset Management first reported a position in Gilead Sciences in Q2 2013 and held it in 42 quarters.
- Doheny Asset Management's Gilead Sciences position peaked at $9.07M in Q2 2015.
- 1,722 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.
Based on Doheny Asset Management's 13F filing for Q1 2024, filed 8 May 2024.